That's incorrect, you're thinking of drugs making it to phase 3. Historically final phase orphan drugs are usually a 55-60% chance of making it through to FDA approval. But agree with the overall sentiment.
- Forums
- ASX - By Stock
- DXB
- Ann: Quarterly Appendix 4C and Activities Report
DXB
dimerix limited
Add to My Watchlist
0.00%
!
50.5¢

Ann: Quarterly Appendix 4C and Activities Report, page-37
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
50.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $294.2M |
Open | High | Low | Value | Volume |
51.0¢ | 51.0¢ | 50.0¢ | $600.8K | 1.192M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 95126 | 50.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
50.5¢ | 92275 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 95117 | 0.500 |
7 | 151104 | 0.495 |
11 | 204083 | 0.490 |
10 | 157135 | 0.485 |
11 | 204248 | 0.480 |
Price($) | Vol. | No. |
---|---|---|
0.505 | 88175 | 4 |
0.510 | 313091 | 6 |
0.515 | 61665 | 4 |
0.520 | 15681 | 2 |
0.525 | 36227 | 1 |
Last trade - 15.41pm 18/06/2025 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online